[Federal Register Volume 87, Number 196 (Wednesday, October 12, 2022)]
[Notices]
[Pages 61601-61605]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22099]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration.
[Docket No. FDA-2022-N-2354]
Generic Drug User Fee Rates for Fiscal Year 2023
AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Federal Food, Drug, and Cosmetic Act (FD&C Act or
statute), as amended by the Generic Drug User Fee Amendments of 2022
(GDUFA III), authorizes the Food and Drug Administration (FDA, Agency,
or we) to assess and collect fees for abbreviated new drug applications
(ANDAs); drug master files (DMFs); generic drug active pharmaceutical
ingredient (API) facilities, finished dosage form (FDF) facilities, and
contract manufacturing organization (CMO) facilities; and generic drug
applicant program user fees. In this document, FDA is announcing fiscal
year (FY) 2023 rates for GDUFA III fees. These fees are effective on
October 1, 2022, and will remain in effect through September 30, 2023.
FOR FURTHER INFORMATION CONTACT: Robert Marcarelli, Office of Financial
Management, Food and Drug Administration, 4041 Powder Mill Rd., Rm.
61075, Beltsville, MD 20705-4304, and the User Fees Support Staff at
[email protected], 301-796-7223.
SUPPLEMENTARY INFORMATION:
I. Background
Sections 744A and 744B of the FD&C Act (21 U.S.C. 379j-41 and 379j-
42), as amended by GDUFA III, authorize FDA to assess and collect fees
associated with human generic drug products. Fees are assessed on: (1)
certain types of applications for human generic drug products; (2)
certain facilities where APIs and FDFs are produced; (3) certain
[[Page 61602]]
DMFs associated with human generic drug products; and (4) generic drug
applicants who have ANDAs (the program fee) (see section 744B(a)(2)
through (5) of the FD&C Act). For more information about GDUFA III,
please refer to the FDA website (https://www.fda.gov/gdufa).
For FY 2023, the generic drug fee rates are: ANDA ($240,582), DMF
($78,293), domestic API facility ($37,544), foreign API facility
($52,544), domestic FDF facility ($213,134), foreign FDF facility
($228,134), domestic CMO facility ($51,152), foreign CMO facility
($66,152), large size operation generic drug applicant program
($1,620,556), medium size operation generic drug applicant program
($648,222), and small business generic drug applicant program
($162,056). These fees are effective on October 1, 2022, and will
remain in effect through September 30, 2023. The fee rates for FY 2023
are set out in table 1.
Table 1--Fee Schedule for FY 2023
------------------------------------------------------------------------
Fees rates for
Generic drug fee category FY 2023
------------------------------------------------------------------------
Applications
Abbreviated New Drug Application (ANDA).......... $240,582
Drug Master File (DMF)........................... 78,293
Facilities
Active Pharmaceutical Ingredient (API)--Domestic. 37,544
API--Foreign..................................... 52,544
Finished Dosage Form (FDF)--Domestic............. 213,134
FDF--Foreign..................................... 228,134
Contract Manufacturing Organization (CMO)--...... 51,152
Domestic
CMO--Foreign..................................... 66,152
GDUFA Program
Large size operation generic drug applicant...... 1,620,556
Medium size operation generic drug applicant..... 648,222
Small business operation generic drug applicant.. 162,056
------------------------------------------------------------------------
II. Fee Revenue Amount for FY 2023
The fee revenue amount for FY 2023 for GDUFA III is $582,500,000.
Since this is the first fiscal year of the GDUFA III authorization
period, there is no inflation adjustment. Applicable inflation
adjustments shall be made beginning with FY 2024.
Beginning with FY 2024, FDA shall, in addition to the inflation
adjustment, apply the capacity planning adjustment under section
744B(c)(2) of the FD&C Act to further adjust, as needed, the fee
revenue and fees to reflect changes in the resource capacity needs of
FDA for human generic drug activities.
Beginning with FY 2024, FDA may, in addition to the inflation and
capacity planning Adjustments, apply the operating reserve adjustment
under section 744B(c)(3) of the FD&C Act to further increase the fee
revenue and fees if necessary to provide operating reserves of
carryover user fees for human generic drug activities for not more than
the number of weeks specified in such section (or as applicable, shall
apply such adjustment to decrease the fee revenues and fees to provide
for not more than 12 weeks of such operating reserves).
III. Fee Amounts for FY 2023
GDUFA III directs FDA to use the annual revenue amount determined
under the statute as a starting point to set the fee rates for each fee
type. The fee revenue amount for FY 2023 is $582,500,000. The ANDA,
DMF, API facility, FDF facility, CMO facility, and generic drug
applicant program fee (GDUFA program fee) calculations for FY 2023 are
described in this document.
A. ANDA Filing Fee
Under GDUFA III, the FY 2023 ANDA filing fee is owed by each
applicant that submits an ANDA on or after October 1, 2022. This fee is
due on the submission date of the ANDA. Section 744B(b)(2)(B) of the
FD&C Act specifies that the ANDA fee will make up 33 percent of the
$582,500,000, which is $192,225,000.
To calculate the ANDA fee, FDA estimated the number of full
application equivalents (FAEs) that will be submitted in FY 2023. The
submissions are broken down into three categories: new originals
(submissions that have not been received by FDA previously);
submissions that FDA refused to receive (RTR) for reasons other than
failure to pay fees; and applications that are resubmitted after an RTR
decision for reasons other than failure to pay fees. An ANDA counts as
one FAE; however, 75 percent of the fee paid for an ANDA that has been
RTR shall be refunded according to GDUFA III if: (1) the ANDA is
refused for a cause other than failure to pay fees or (2) the ANDA has
been withdrawn prior to receipt (section 744B(a)(3)(D)(i) of the FD&C
Act). Therefore, an ANDA that is considered not to have been received
by FDA due to reasons other than failure to pay fees or withdrawn prior
to receipt counts as one-fourth of an FAE. After an ANDA has been RTR,
the applicant has the option of resubmitting. For user fee purposes,
these resubmissions are equivalent to new original submissions: ANDA
resubmissions are charged the full amount for an application (one FAE).
FDA utilized data from ANDAs submitted from October 1, 2020, to
April 30, 2022, to estimate the number of new original ANDAs that will
incur filing fees in FY 2023. For FY 2023, FDA estimates that
approximately 800 new original ANDAs will be submitted and incur filing
fees. Not all of the new original ANDAs will be received by FDA and
some of those not received will be resubmitted in the same fiscal year.
Therefore, FDA expects that the FAE count for ANDAs will be 799 for FY
2023.
The FY 2023 application fee is estimated by dividing the number of
FAEs that will pay the fee in FY 2023 (799) into the fee revenue amount
to be derived from ANDA application fees in FY 2023 ($192,225,000). The
result, rounded to the nearest dollar, is a fee of $240,582 per ANDA.
The statute provides that those ANDAs that include information
about the production of APIs other than by reference to a DMF will pay
an additional fee that is based on the number of such APIs and the
number of
[[Page 61603]]
facilities proposed to produce those ingredients (see section
744B(a)(3)(F) of the FD&C Act). FDA anticipates that this additional
fee is unlikely to be assessed often; therefore, FDA has not included
projections concerning the amount of this fee in calculating the fees
for ANDAs.
B. DMF Fee
Under GDUFA III, the DMF fee is owed by each person that owns a
type II API DMF that is referenced, on or after October 1, 2012, in a
generic drug submission by an initial letter of authorization. This is
a one-time fee for each DMF. This fee is due on the earlier of the date
on which the first generic drug submission is submitted that references
the associated DMF or the date on which the DMF holder requests the
initial completeness assessment. Under section 744B(a)(2)(D)(iii) of
the FD&C Act, if a DMF has successfully undergone an initial
completeness assessment and the fee is paid, the DMF will be placed on
a publicly available list documenting DMFs available for reference.
To calculate the DMF fee, FDA assessed the volume of DMF
submissions over time. We assessed DMFs from October 1, 2020, to April
30, 2022, and concluded that averaging the number of fee-paying DMFs
provided the most accurate model for predicting fee-paying DMFs for FY
2023. The monthly average of paid DMF submissions FDA received in FY
2021 and FY 2022 is 31. To determine the FY 2023 projected number of
fee-paying DMFs, the average of 31 DMF submissions is multiplied by 12
months, which results in 372 estimated FY 2023 fee-paying DMFs. FDA is
estimating 372 fee-paying DMFs for FY 2023.
The FY 2023 DMF fee is determined by dividing the DMF target
revenue by the estimated number of fee-paying DMFs in FY 2023. Section
744B(b)(2)(A) of the FD&C Act specifies that the DMF fees will make up
5 percent of the $582,500,000, which is $29,125,000. Dividing the DMF
revenue amount ($29,125,000) by the estimated fee-paying DMFs (372),
and rounding to the nearest dollar, yields a DMF fee of $78,293 for FY
2023.
C. Foreign Facility Fee Differential
Under GDUFA III, the fee for a facility located outside the United
States and its territories and possessions shall be $15,000 higher than
the amount of the fee for a facility located in the United States and
its territories and possessions. The basis for this differential is the
extra cost incurred by conducting an inspection outside the United
States and its territories and possessions.
D. FDF and CMO Facility Fees
Under GDUFA III, the annual FDF facility fee is owed by each person
who owns an FDF facility that is identified in at least one approved
generic drug submission owned by that person or its affiliates. The CMO
facility fee is owed by each person who owns an FDF facility that is
identified in at least one approved ANDA but is not identified in an
approved ANDA held by the owner of that facility or its affiliates.
Section 744B(b)(2)(C) of the FD&C Act specifies that the FDF and CMO
facility fee revenue will make up 20 percent of the $582,500,000, which
is $116,500,000.
To calculate the fees, data from FDA's Integrity Services (IS) were
utilized as the primary source of facility information for determining
the denominators of each facility fee type. IS is the master data
steward for all facility information provided in generic drug
submissions received by FDA. A facility's reference status in an
approved generic drug submission is extracted directly from submission
data rather than relying on data from self-identification. This
information provided the number of facilities referenced as FDF
manufacturers in at least one approved generic drug submission. Based
on FDA's IS data, the FDF and CMO facility denominators are 176 FDF
domestic, 293 FDF foreign, 90 CMO domestic, and 114 CMO foreign
facilities for FY 2023.
GDUFA III specifies that the CMO facility fee is to be equal to 24
percent of the FDF facility fee. Therefore, to generate the target
collection revenue amount from FDF and CMO facility fees
($116,500,000), FDA must weight a CMO facility as 24 percent of an FDF
facility. FDA set fees based on the estimate of 176 FDF domestic, 293
FDF foreign, 21.60 CMO domestic (90 multiplied by 24 percent), and
27.36 CMO foreign facilities (114 multiplied by 24 percent), which
equals 518 total weighted FDF and CMO facilities for FY 2023.
To calculate the fee for domestic facilities, FDA first determines
the total fee revenue that will result from the foreign facility
differential by subtracting the fee revenue resulting from the foreign
facility fee differential from the target collection revenue amount
($116,500,000) as follows: the foreign facility fee differential
revenue equals the foreign facility fee differential ($15,000)
multiplied by the number of FDF foreign facilities (293) plus the
foreign facility fee differential ($15,000) multiplied by the number of
CMO foreign facilities (114), totaling $6,105,000. This results in
foreign fee differential revenue of $6,105,000 from the total FDF and
CMO facility fee target collection revenue.
Subtracting the foreign facility differential fee revenue
($6,105,000) from the total FDF and CMO facility target collection
revenue ($116,500,000) results in a remaining facility fee revenue
balance of $110,395,000. To determine the domestic FDF facility fee,
FDA divides the $110,395,000 by the total weighted number of FDF and
CMO facilities (518), which results in a domestic FDF facility fee of
$213,134. The foreign FDF facility fee is $15,000 more than the
domestic FDF facility fee, or $228,134.
According to GDUFA III, the domestic CMO fee is calculated as 24
percent of the amount of the domestic FDF facility fee. Therefore, the
domestic CMO fee is $51,152, rounded to the nearest dollar. The foreign
CMO fee is calculated as the domestic CMO fee plus the foreign fee
differential of $15,000. Therefore, the foreign CMO fee is $66,152.
E. API Facility Fee
Under GDUFA III, the annual API facility fee is owed by each person
who owns a facility that is identified in: at least one approved
generic drug submission or a Type II API DMF referenced in at least one
approved generic drug submission. Section 744B(b)(2)(D) of the FD&C Act
specifies the API facility fee will make up 6 percent of $582,500,000
in fee revenue, which is $34,950,000.
To calculate the API facility fee, data from FDA's IS were utilized
as the primary source of facility information for determining the
denominator. As stated above, IS is the master data steward for all
facility information provided in generic drug submissions received by
FDA. A facility's reference status in an approved generic drug
submission is extracted directly from submission data rather than
relying on data from self-identification. This information provided the
number of facilities referenced as API manufacturers in at least one
approved generic drug submission.
The total number of API facilities identified was 688; of that
number, 80 were domestic and 608 were foreign facilities. The foreign
facility differential is $15,000. To calculate the fee for domestic
facilities, FDA must first subtract the fee revenue that will result
from the foreign facility fee differential. FDA takes the foreign
facility differential ($15,000) and multiplies it by the number of
foreign facilities (608) to determine the total fee revenue that
[[Page 61604]]
will result from the foreign facility differential. As a result of this
calculation, the foreign fee differential revenue will make up
$9,120,000 of the total API fee revenue. Subtracting the foreign
facility differential fee revenue ($9,120,000) from the total API
facility target revenue ($34,950,000) results in a remaining balance of
$25,830,000. To determine the domestic API facility fee, we divide the
$25,830,000 by the total number of facilities (688), which gives us a
domestic API facility fee of $37,544. The foreign API facility fee is
$15,000 more than the domestic API facility fee, or $52,544.
F. Generic Drug Applicant Program Fee
Under GDUFA III, if a person and its affiliates own at least one
but not more than five approved ANDAs on October 1, 2022, the person
and its affiliates shall owe a small business GDUFA program fee. If a
person and its affiliates own at least 6 but not more than 19 approved
ANDAs, the person and its affiliates shall owe a medium size operation
GDUFA program fee. If a person and its affiliates own at least 20
approved ANDAs, the person and its affiliates shall owe a large size
operation GDUFA program fee. Section 744B(b)(2)(E) of the FD&C Act
specifies the GDUFA program fee will make up 36 percent of $582,500,000
in fee revenue, which is $209,700,000.
To determine the appropriate number of parent companies for each
tier, FDA asked companies to claim their ANDAs and affiliates in the
Center for Drug Evaluation and Research (CDER) NextGen Portal. The
companies were able to confirm relationships currently present in FDA's
records, while also reporting newly approved ANDAs, newly acquired
ANDAs, and new affiliations.
In determining the appropriate number of approved ANDAs, FDA has
factored in a number of variables that could affect the collection of
the target revenue: (1) inactive ANDAs: applicants who have not
submitted an annual report for one or more of their approved
applications within the past 2 years; (2) Program Fee Arrears List:
parent companies that are on the arrears list for any fiscal year; (3)
Large Tier Adjustment: the frequency of large-tiered companies dropping
to the medium tier and medium-tiered companies moving to the large tier
after the completion of the program fee methodology and tier
determination; (4) Center for Biologics Evaluation and Research (CBER)
approved ANDAs: applicants and their affiliates with CBER-approved
ANDAs in addition to CDER's approved ANDAs; and (5) withdrawals of
approved ANDAs by April 1: applicants who have submitted a written
request for withdrawal of approval by April 1 of the previous fiscal
year.
The list of original approved ANDAs from the Generic Drug Review
Platform as of April 30, 2022, shows 253 applicants in the small
business tier, 75 applicants in the medium size tier, and 79 applicants
in the large size tier. Factoring in all the variables, we estimate
there will be 220 applicants in the small business tier, 76 applicants
in the medium size tier, and 77 applicants in the large size tier for
FY 2023.
To calculate the GDUFA program fee, GDUFA III provides that large
size operation generic drug applicants pay the full fee, medium size
operation applicants pay two-fifths of the full fee, and small business
applicants pay one-tenth of the full fee. To generate the target
collection revenue amount from GDUFA program fees ($209,700,000), we
must weigh medium and small tiered applicants as a subset of a large
size operation generic drug applicant. FDA will set fees based on the
weighted estimate of 22 applicants in the small business tier (220
multiplied by 10 percent), 30.4 applicants in the medium size tier (76
multiplied by 40 percent), and 77 applicants in the large size tier,
arriving at 129.4 total weighted applicants for FY 2023.
To generate the large size operation GDUFA program fee, FDA divides
the target revenue amount of $209,700,000 by 129.4, which equals
$1,620,556. The medium size operation GDUFA program fee is 40 percent
of the full fee ($648,222), and the small business operation GDUFA
program fee is 10 percent of the full fee ($162,056).
IV. Fee Schedule For FY 2023
The fee rates for FY 2023 are set out in table 2.
Table 2--Fee Schedule for FY 2023
------------------------------------------------------------------------
Fees rates for
Generic drug fee category FY 2023
------------------------------------------------------------------------
Applications:
Abbreviated New Drug Application (ANDA).......... $240,582
Drug Master File (DMF)........................... 78,293
Facilities:
Active Pharmaceutical Ingredient (API)--Domestic. 37,544
API--Foreign..................................... 52,544
Finished Dosage Form (FDF)--Domestic............. 213,134
FDF--Foreign..................................... 228,134
Contract Manufacturing Organization (CMO)--...... 51,152
Domestic:
CMO--Foreign..................................... 66,152
GDUFA Program:
Large size operation generic drug applicant...... 1,620,556
Medium size operation generic drug applicant..... 648,222
Small business operation generic drug applicant.. 162,056
------------------------------------------------------------------------
V. Fee Payment Options and Procedures
The new fee rates are effective October 1, 2022, and will remain in
effect through September 30, 2023. Under sections 744B(a)(4) and (5) of
the FD&C Act, respectively, facility and program fees are generally due
on the later of the first business day on or after October 1 of each
fiscal year or the first business day after the enactment of an
appropriations act providing for the collection and obligation of GDUFA
fees for the fiscal year. Here, that date is October 3, 2022. However,
given the late date of the GDUFA reauthorization for FYs 2023 through
2027, facility and program fees for FY 2023 should be paid within 30
days from the issue date of this notice.
[[Page 61605]]
To pay the ANDA, DMF, API facility, FDF facility, CMO facility, and
GDUFA program fees, a Generic Drug User Fee Cover Sheet must be
completed, available at https://www.fda.gov/gdufa and https://
userfees.fda.gov/OA_HTML/gdufaCAcdLogin.jsp, and a user fee
identification (ID) number must be generated. Payment must be made in
U.S. currency drawn on a U.S. bank by electronic check, check, bank
draft, U.S. postal money order, credit card, or wire transfer. The
preferred payment method is online using electronic check (Automated
Clearing House (ACH), also known as eCheck) or credit card (Discover,
VISA, MasterCard, American Express). FDA has partnered with the U.S.
Department of the Treasury to utilize Pay.gov, a web-based payment
application, for online electronic payment. The Pay.gov feature is
available on the FDA website after completing the Generic Drug User Fee
Cover Sheet and generating the user fee ID number.
Secure electronic payments can be submitted using the User Fees
Payment Portal at https://userfees.fda.gov/pay. (Note: only full
payments are accepted; no partial payments can be made online.) Once an
invoice is located, ``Pay Now'' should be selected to be redirected to
Pay.gov. Electronic payment options are based on the balance due.
Payment by credit card is available for balances less than $25,000. If
the balance exceeds this amount, only the ACH option is available.
Payments must be made using U.S. bank accounts as well as U.S. credit
cards.
The user fee ID number must be included on the check, bank draft,
or postal money order and must be made payable to the order of the Food
and Drug Administration. Payments can be mailed to: Food and Drug
Administration, P.O. Box 979108, St. Louis, MO 63197-9000. If checks
are to be sent by a courier that requests a street address, the courier
can deliver checks to U.S. Bank, Attention: Government Lockbox 979108,
1005 Convention Plaza, St. Louis, MO 63101. (Note: This U.S. Bank
address is for courier delivery only. For questions concerning courier
delivery, U.S. Bank can be contacted at 314-418-4013. This telephone
number is only for questions about courier delivery.) The FDA post
office box number (P.O. Box 979108) must be written on the check, bank
draft, or postal money order.
For payments made by wire transfer, the unique user fee ID number
must be referenced. Without the unique user fee ID number, the payment
may not be applied. If the payment amount is not applied, the invoice
amount will be referred to collections. The originating financial
institution may charge a wire transfer fee. Applicable wire transfer
fees must be included with payment to ensure fees are fully paid.
Questions about wire transfer fees should be addressed to the financial
institution. The following account information should be used to send
payments by wire transfer: U.S. Department of the Treasury, TREAS NYC,
33 Liberty St., New York, NY 10045, account number: 75060099, routing
number: 021030004, SWIFT: FRNYUS33. FDA's tax identification number is
53-0196965.
Dated: October 5, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-22099 Filed 10-6-22; 11:15 am]
BILLING CODE 4164-01-P